7,652 Shares in Abbott Laboratories $ABT Purchased by Matters Capital LLC

Matters Capital LLC bought a new stake in Abbott Laboratories (NYSE:ABT) during the second quarter, Holdings Channel.com reports. The institutional investor bought 7,652 shares of the healthcare product maker’s stock, valued at approximately $694,000.

A number of other institutional investors have also made changes to their positions in ABT. J. Stern & Co. LLP raised its stake in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares during the period. Norges Bank purchased a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $2,938,892,000. Flossbach Von Storch SE acquired a new stake in Abbott Laboratories in the 2nd quarter valued at approximately $902,938,000. BlackRock Inc. raised its position in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Abbott Laboratories by 217.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock worth $566,967,000 after purchasing an additional 3,780,402 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Down 1.8%

NYSE:ABT opened at $110.48 on Tuesday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The firm has a market cap of $191.17 billion, a PE ratio of 35.75, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a fifty day moving average price of $103.06 and a 200 day moving average price of $100.13.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s payout ratio is currently 81.55%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Wells Fargo & Company raised their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. raised their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Citigroup lifted their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. TD Cowen increased their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Finally, Bank of America lowered their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.